



CASE REPORT

Dyspnea in antiphospholipid syndrome: Beyond pulmonary embolism



Carolina Sepúlveda^{a,b,*}, Débora Repolho^c, Ana Margarida Antunes^a,
Anna Viola Taulaigo^a, Filipa Carreiro^{a,d}, Rui Cruz Ferreira^e,
Maria Francisca Moraes-Fontes^a, Maria José Loureiro^c

^a Unidade de Doenças Autoimunes, Medicina 7.2, Hospital Curry Cabral – Centro Hospitalar Lisboa Central (CHLC), Lisboa, Portugal

^b Serviço de Medicina Interna, Hospital de Abrantes – Centro Hospitalar Médio Tejo (CHMT), Abrantes, Portugal

^c Unidade de Hipertensão Pulmonar, Serviço de Cardiologia – Hospital Garcia de Orta (HGO), Almada, Portugal

^d Serviço de Medicina Interna – Hospital do Divino Espírito Santo (HDES), Ponta Delgada, Portugal

^e Serviço de Cardiologia, Hospital de Santa Marta – CHLC, Lisboa, Portugal

Received 20 September 2017; accepted 15 January 2018

KEYWORDS

Antiphospholipid syndrome;
Pulmonary embolism;
Chronic thromboembolic pulmonary hypertension;
Pulmonary endarterectomy

Abstract Pulmonary embolism due to primary antiphospholipid syndrome is rarely associated with chronic thromboembolic pulmonary hypertension, and therefore according to the latest guidelines on pulmonary hypertension, routine screening is not recommended. We describe a young patient with a late diagnosis of chronic thromboembolic pulmonary hypertension in the context of pulmonary embolism, primary antiphospholipid syndrome and suboptimal anticoagulation. Of note, mild cardiopulmonary symptoms were consistently misattributed to a depressive disorder because physical examination was normal, serial Doppler echocardiography failed to show pulmonary hypertension, and all other diagnostic tests were normal. Once symptoms became severe, positive screening tests led to the correct diagnosis and surgical referral, and bilateral pulmonary endarterectomy was successfully performed. This case demonstrates the need for extra awareness in patients with antiphospholipid syndrome and pulmonary embolism. © 2020 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALAVRAS-CHAVE

Síndrome antifosfolípido;
Embolia pulmonar;

Dispneia na síndrome anticorpo antifosfolípido: para além da embolia pulmonar

Resumo A embolia pulmonar devido à síndrome de anticorpo antifosfolípido raramente está associada a hipertensão pulmonar crónica tromboembólica, pelo que o seu rastreio não

* Corresponding author.

E-mail address: sc.carolina@gmail.com (C. Sepúlveda).

Hipertensão pulmonar tromboembólica crônica; Hipertensão pulmonar

está recomendado pelas normas de orientação clínica atuais. Descreve-se o caso de uma doente jovem com o diagnóstico tardio de hipertensão pulmonar crônica tromboembólica no contexto de síndrome de anticorpo antifosfolípido primário e anticoagulação subterapêutica. A destacar que a sintomatologia cardiopulmonar de grau ligeiro foi incorretamente atribuída a humor depressivo devido à ausência de alterações no exame objetivo e nos meios complementares de diagnóstico, incluindo valores persistentemente normais de pressão sistólica da artéria pulmonar nos ecocardiogramas transtorácicos seriados. O agravamento sintomático progressivo conduziu à confirmação diagnóstica, após realização dos meios complementares de diagnóstico de rastreio, referência cirúrgica e realização de endarterectomia pulmonar bilateral com sucesso. Este caso demonstra a necessidade de uma vigilância mais apertada em doentes com síndrome de anticorpo antifosfolípido e embolia pulmonar.

© 2020 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. Este é um artigo Open Access sob uma licença CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Pulmonary embolism (PE) due to primary antiphospholipid syndrome (APS) may be associated with chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) characterized by impaired dissolution of thrombi due to pulmonary embolism (PE) persisting beyond 3-6 months of adequate anticoagulation.¹⁻⁴ CTEPH is a life-threatening condition of unpredictable onset,⁵ and, in the setting of APS, may occur soon after the thrombotic event.⁶ We report a young patient in whom CTEPH was diagnosed late in the course of the disease, with a favorable therapeutic outcome. Notwithstanding its rarity, we aim to raise awareness of the possibility of PH development in patients with APS.

Case report

In 1993, a previously healthy 20-year-old nulliparous female suffered a PE secondary to an unprovoked peripheral deep vein thrombosis (DVT), after which she was treated with warfarin for nine months. Three months later she suffered a second DVT. At this time inherited thrombophilia disorders were excluded, lupus anticoagulant was persistently positive and she was diagnosed with primary APS. Despite a recommendation for life-long anticoagulation with warfarin, she only adhered to the therapy for six months.

In 2003 (aged 30), she was referred to our unit. Although she was not taking any medication, no further thromboembolic episodes had occurred. Nevertheless, she was suffering from anorexia, anxiety and depression, and had been prescribed fluoxetine 20 mg/day. Warfarin was restarted. In 2006 (aged 33), 13 years after the PE, she began complaining of asthenia, fatigue and mild effort dyspnea, but there were no relevant findings on physical examination. Full blood count and liver and renal function tests were normal; transthoracic echocardiography (TTE) showed no anatomical or functional changes, including normal estimated pulmonary artery systolic pressure (PASP) on Doppler TTE; thoracic computed tomography (CT) revealed no signs

of interstitial lung disease. Over the following years her symptoms slowly increased in severity and she was unable to work. Retrieved monthly international normalized ratio records ranged between 2.0 and 4.0 after 2006. The pattern in serial TTEs remained unchanged and her symptoms were consistently attributed to persistent depression.

In 2013 (aged 40), at a routine follow-up appointment, she complained of severe exertional dyspnea and palpitations. Physical examination revealed central cyanosis and tachycardia, and peripheral capillary oxygen saturation (SpO₂) was under 90%. Blood tests showed polycythemia and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP). Doppler TTE showed an estimated PASP of 100 mmHg (normal <35 mmHg⁷) and she was promptly referred to a specialist pulmonary hypertension center. Further investigations were as follows: pulmonary function tests were normal; the six-minute walk test (Table 1) revealed normal chronotropic and inotropic competence on exertion but reduced functional performance (75% of normal)⁸; the pulmonary ventilation/perfusion scan (Figure 1A) indicated subsegmental perfusion defects with preserved ventilation of all the left lobe segments and of the superior and posterior basal segments of the right lobe; CT angiography (Figure 1B) showed a subocclusive stenotic lesion at the origin of the left inferior lobar artery and bilateral involvement of lobar and peripheral branches; right heart catheterization (Table 1) disclosed low cardiac output and index, elevated mean pulmonary artery pressure, pulmonary vascular resistance three times the upper limit of normal, and pulmonary artery wedge pressure below the threshold, overall indicative of moderate precapillary PH; and pulmonary angiography (Video 1) showed multiple filling defects with total occlusion of the left inferior lobar artery in addition to several segments of the right superior and inferior lobes.

Pulmonary endarterectomy was performed through a median sternotomy approach at an international reference center for CTEPH in March 2015, with full bilateral removal of thrombi and fibrotic material (Figure 2). There were no postoperative complications and follow-up tests (Table 1)

Table 1 Characterization of parameters and hemodynamics before and after pulmonary endarterectomy.

Diagnostic method	Feature assessed	Before PEA	6 months after PEA	2 years after PEA	Normal
Clinical symptoms	Signs of right heart failure	Yes	No	No	-
	WHO	III	II	I	-
6-min walk test	Distance, m (% of expected)	450 (75)	480 (80)	480 (83)	600 (≥ 75)
	MBS				
	at rest	5	0	1	<1
	at peak effort	8	0	1	
Blood test	SpO ₂ , %	87	90	93	≥ 96
	NT-proBNP, pg/ml	489	165	193	<153
Right heart catheterization	mPAP, mmHg	51	30	21	<25
	PAWP, mmHg	15	11	9	≤ 15
	CO (Fick), l/min	3.98	5.42	4.5	>5
	CI (Fick), l/min/m ²	2.33	3.28	2.8	>2.4
	PVR (Fick), Wood units	9.04	3.5	2.81	≤ 3

CI (Fick): cardiac index by Fick's method; CO (Fick): cardiac output by Fick's method; MBS: modified Borg scale; mPAP: mean pulmonary arterial pressure; NT-proBNP: N-terminal pro-B-type natriuretic peptide; PASP: pulmonary artery systolic pressure; PAWP: pulmonary artery wedge pressure; PEA: pulmonary endarterectomy; PVR (Fick): pulmonary vascular resistance by Fick's method; SpO₂: peripheral capillary oxygen saturation; WHO: World Health Organization functional class.




Figure 1 Initial diagnostic procedures. (A) Pulmonary ventilation/perfusion scan with subsegmental perfusion defects (blue arrows) and preserved ventilation in the left lower lobe; (B) computed tomography angiography with a subocclusive stenotic lesion at the origin of the left inferior lobar artery (red arrows). Ant_P: anterior-posterior; L: left; Post-P: postero-posterior; R: right; RPO_P: right posterior oblique-posterior.

showed improvements in all parameters, most noticeably WHO functional class, six-minute walk distance, biochemical markers (NT-proBNP) and hemodynamic parameters on right heart catheterization.

At the present time, more than two years after surgery, the patient is asymptomatic (WHO functional class I). Furthermore, her quality of life has improved significantly, allowing her to keep a full-time job. She remains under



Figure 2 Surgical specimen: fibrotic thrombi enveloped by thickened intima removed by pulmonary endarterectomy.

lifelong oral anticoagulation with warfarin without need for additional pulmonary vasodilator therapy.

Discussion and Conclusions

CTEPH is a rare disorder with a reported prevalence of 3 and 63 per million individuals in Europe and in the USA, respectively.^{9,10} Its incidence is low (reported as 0.57%¹¹ and 4-5%¹² after PE), and as it can occur up to two years after an acute thrombotic episode,^{1,6} routine screening for CTEPH after PE is not supported by current evidence.⁴ Thrombus size, immune-mediated mechanisms, elevated factor VIII, thyroid replacement, structural cardiac abnormalities and malignancy have also been reported as being associated with CTEPH.^{3,13-15} However, its etiology remains unclear, as it may develop in the absence of PE,^{16,17} despite adequate anticoagulation and in association with generalized pulmonary vasculopathy.¹

Of note, our patient was asymptomatic for 12 years after the last thrombotic event. Although cardiopulmonary symptoms were observed, their insidious nature led to misattribution to a depressive disorder. Detection of PH by TTE remains a challenge^{18,19} and we recognize that the patient might have benefited from an earlier diagnostic work-up. Moreover, she had various known risk factors for CTEPH, including several thrombotic episodes, a background of autoimmunity and a prolonged period of inadequate therapy, which collectively may have contributed to impaired thrombus resolution. Pulmonary endarterectomy is a complex surgical procedure, but it not only arrests the malignant natural course of the disease that results in premature mortality but also leads to hemodynamic and functional improvement.^{1,2,5,20} Our patient requires life-long monitoring and anticoagulation, as there are no known prognostic markers that indicate the possibility of disease recurrence.

In conclusion, CTEPH is rare but fatal if left untreated and there should therefore be a high level of suspicion for non-specific symptoms, despite the presence of depression and especially when there is a history of previous venous thromboembolism.²⁰ APS and failure to adhere to anticoagulant therapy should raise the bar for CTEPH screening.

Conflicts of interest

The authors have no conflicts of interest or financial disclosures to declare.

Acknowledgments

Mr. David Jenkins, Clinical Director of Surgery and Consultant Cardiothoracic Surgeon at the Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, was responsible for the pulmonary endarterectomy.

Appendix A. Supplementary material

Supplementary material associated with this article can be found in the online version at [doi:10.1016/j.repc.2018.01.015](https://doi.org/10.1016/j.repc.2018.01.015).

References

1. Edward JA, Mandras S. An update on the management of chronic thromboembolic pulmonary hypertension. *Curr Probl Cardiol.* 2017;42:7-38.
2. Jenkins D, Madani M, Fadel E, et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. *Eur Respir Rev.* 2017;26.
3. Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. *Am J Med.* 1994;96:3-9.
4. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J.* 2016;37:67-119.
5. Robbins IM, Pugh ME, Hemnes AR. Update on chronic thromboembolic pulmonary hypertension. *Trends Cardiovasc Med.* 2017;27:29-37.

6. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med*. 2004;350:2257–64.
7. Santas E, de la Espriella-Juan R, Mollar A, et al. Echocardiographic pulmonary artery pressure estimation and heart failure rehospitalization burden in patients with acute heart failure. *Int J Cardiol*. 2017;241:407–10.
8. Enright PL, McBurnie MA, Bittner V, et al. The 6-min walk test: a quick measure of functional status in elderly adults. *Chest*. 2003;123:387–98.
9. Divers C, Platt D, Wang E, et al. A review of clinical trial endpoints of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension and how they relate to patient outcomes in the United States. *J Manag Care Spec Pharm*. 2017;23:92–104.
10. Escribano-Subias P, Blanco I, Lopez-Meseguer M, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. *Eur Respir J*. 2012;40:596–603.
11. Klok FA, van Kralingen KW, van Dijk AP, et al. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. *Haematologica*. 2010;95:970–5.
12. Madani MM. Surgical treatment of chronic thromboembolic pulmonary hypertension: pulmonary thromboendarterectomy. *Methodist Debaquey Cardiovasc J*. 2016;12:213–8.
13. Bonderman D, Turecek PL, Jakowitsch J, et al. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. *Thromb Haemost*. 2003;90:372–6.
14. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2009;33:325–31.
15. Lang IM, Simonneau G, Pepke-Zaba JW, et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. *Thromb Haemost*. 2013;110:83–91.
16. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. *Circulation*. 2011;124:1973–81.
17. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. *Eur Respir J*. 2000;15:440–8.
18. Sciomer S, Badagliacca R, Fedele F. Pulmonary hypertension: echocardiographic assessment. *Ital Heart J*. 2005;6:840–5.
19. Wright LM, Dwyer N, Celermajer D, et al. Follow-up of pulmonary hypertension with echocardiography. *JACC Cardiovasc Imaging*. 2016;9:733–46.
20. Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. *Circulation*. 2014;130:508–18.